Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS- Kaposi's sarcoma xenograft

Blood

Volumn 95, Issue 11, 2000, Pages 3506-3513

  Husain, Syed R ^a   Puri, Raj K ^a,b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Natl Institutes of Health Bldg 29B   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR; PSEUDOMONAS EXOTOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG TISSUE LEVEL; HUMAN; HUMAN CELL; KAPOSI SARCOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR REGRESSION; XENOGRAFT;

EID: 0034210937     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.11.3506     Document Type: Article

References (38)

1. Kaaya EE, Parracicini C, Ordonez R, Gendelman E, Berti, Gallo RC. Heterogeneity of spindle cells in Kaposi's sarcoma: comparison of cells in lesion and in culture. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10:295.
2. Ensoli B, Sirianni MC. Kaposi's sarcoma pathogenesis: a link between immunology and tumor biology. Crit Rev Oncog. 1998;9:107.
3. Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N Engl J Med. 1995;332:1181.
4. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994;265:1865.
5. Monini P, Colombini S, Sturzl M, et al. Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma. Blood. 1999;93:4044.
6. Aoki Y, Jaffe ES, Chang Y, et al. Angiogenesis and hematopoiesis induced by Kaposi's sarcomaassociated herpesvirus-encoded interleukin-6. Blood. 1999;93:4034.
7. Mesri EA. Inflammatory reactivation and angiogenicity of Kaposi's sarcoma-associated herpesvirus/HHV8: a missing link in the pathogenesis of acquired immunodeficiency syndrome-associated Kaposi's sarcoma. Blood. 1999;93:4031.
8. Ensoli B, Nakamura S, Salahuddin SZ, et al. AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth factors. Science. 1989;243:223.
9. Ganem D, Viruses, cytokines and Kaposi's sarcoma. Curr Biol. 1995;5:469.
10. Ensoli B, Barillari G, Gallo RC. Cytokines and growth factors in the pathogenesis of AIDS-associated Kaposi's sarcoma. Immunol Rev. 1992; 127:147.
11. Miles SA, Rezai AR, Salazar-Gonzalez JF, et al. AIDS Kaposi's sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci U S A. 1990;87:4068.
12. Hermans P, Gori A, Lemone M, Franchioly P, Clumeck N. Possible role of granulocyte-macrophage colony stimulating factor (GM-CSF) on the rapid progression of AIDS-related Kaposi's sarcoma lesions in vivo. Br J Haematol. 1994;87: 413.
13. Maier JAM, Mariotti M, Albini A, et al. Overexpression of hapatocyte growth factor in human Kaposi's sarcoma. Int J Cancer. 1996;65:168.
14. Stürzl M, Roth WK, Brockmeyer NH, Zietz C, Speiser B, Hofschneider PH. Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi's sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance. Proc Natl Acad Sci USA. 1992;89: 7046.
15. Husain SR, Gill P, Kreitman RJ, Pastan I, Puri RK. Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin. Mol Med. 1997;3:327.
16. 389-IL-4). Invest New Drugs. 1997;15:279.
17. Masood R, Lunardi-Iskandar Y, Lee FL, et al. AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth factors. AIDS Res Hum Retroviruses. 1994;10: 969.
18. Masood R, Cai J, Zheng T, Smith DL, Naidu Y, Gill PS. Inhibition of AIDS-associated Kaposi's sarcoma cell growth by DAB389-interleukin 6. Proc Natl Acad Sci U S A. 1997;94:979.
19. Husain SR, Obiri NI, Gill P, et al. Receptors for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein. Clin Cancer Res. 1997;3:151.
20. Brown KD, Zurawski SM, Mosmann TR, Zurawski G. A family of small inducible proteins secreted by leukocytes are members of a new superfamily that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processes. J Immunol. 1989; 142:679.
21. Minty A, Chalon P, Derocq J-M, et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature. 1993;362:248.
22. Obiri NI, Debinski W, Leonard WJ, Puri RK. Receptor for inlerleukin 13: interaction with interleukin 4 by a mechanism that does not involve the common γ chain shared by receptors for interleukin 2, 4, 7, 9, and 15. J Biol Chem. 1995;270: 8797.
23. Montaner LJ, Doyle AG, Collin M, et al. Interleukin 13 inhibits human immunodeficiency virus type 1 production in primary blood-derived human macrophages in vitro. J Exp Med. 1993;178:743.
24. Debinski W, Obiri NI, Pastan I, Puri RK. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J Biol Chem. 1995;270:16,775.
25. Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin. Clin Cancer Res. 1995;1:1253.
26. Puri RK, Leland P, Obiri NI, et al. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A. Blood. 1996;67: 4333.
27. Masood R, McGarvey ME, Zheng T, et al. Antineoplastic urinary protein inhibits Kaposi's sarcoma and angiogenesis in vitro and in vivo. Blood. 1999;93:1038.
28. Albini A, Paglieri I, Orengo G, et al. The beta-core fragment of human chorionic gonadotropin inhibits growth of Kaposi's sarcoma-derived cells and a new immortalized Kaposi's sarcoma cell line. AIDS. 1997;11:713.
29. Munson PJ, Rodbard D. Ligand: a versatile computerized approach for characterization of ligandbinding systems. Anal Biochem. 1980;107:220.
30. Murata T, Husain SR, Mohri H, Puri RK. Two different IL-13 receptor chains are expressed in normal human skin fibroblasts, and IL-4 and IL-13 mediates signal transduction through a common pathway. Int Immunol. 1998;10:1103.
31. Husain SR, Kreitman RJ, Pastan I, Puri RK. Interleukin-4 receptor directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model. Nat Med. 1999;5:817.
32. Husain SR, Behari N, Kreitman RJ, Pastan I, Puri RK. Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy. Cancer Res. 1998;58:3649.
33. Debinski W, Gibo D, Obiri NI, Kealiher A, Puri RK. Novel anti-brain tumor cytotoxins specific for cancer cells. Nat Biotechnol. 1998;16:449.
34. Gills PS, Herman A, Naidu Y. Epidemic (AIDS-related) Kaposi's sarcoma: epidemiology, pathogenesis and treatment. AIDS Updates. 1994;7:1.
35. Murata T, Obiri NI, Debinski W, Puri RK. Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem Biophys Res Comm. 1997;238:90.
36. Murata T, Obiri NI, Puri RK. Structure and signal transduction through interleukin-4 and interleukin-13 receptors (review). Int J Mol Med. 1998; 1:551.
37. Zurawski SM, Chomarat P, Djossou O, et al. The primary binding subunit of the human interleukin-4 receptor is also a component of the interleukin-13 receptor. J Biol Chem. 1995;270:13,869.
38. 389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood. 1998;91:399.